Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation

University Hospital, Toulouse101 enrolled

Overview

This chart review describe the response to systemic chemotherapy of patients with non-small cell lung cancer (NSCLC) harbouring a known somatic activating human epidermal growth factor receptor 2 (HER2) mutation. The analysis of this data will provide an initial description of the response to systemic chemotherapy in patients with NSCLC harboring an activating HER2 mutation in order to inform the design and powering of future randomized controlled clinical trials of HER2-directed therapy.

Study Type

OBSERVATIONAL

Enrollment

101

Conditions

Lung Cancer

Interventions

No specific interventionOTHER

Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with advanced nonsmall-cell lung cancer * known HER2 exon-20 insertion * treated with chemotherapy and/or HER2-targeted drugs Exclusion Criteria: * none

Outcomes

Primary Outcomes

Overall response rate

Time frame: 24 months

Secondary Outcomes

Median progression-free survival (PFS) with conventional chemotherapy

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.